Co nas w kościach strzyka... czyli choroby szpiku a innowacyjne leki

*Dorota Dziuban¹, Paweł Kowalczyk², Maciej Filocha²

Summary
Bone marrow and it contains stem cells needed to produce health and life of blood cells: red blood cells (erythrocytes), white blood cells (leukocytes) and platelets. The latter are mainly responsible for coagulation processes in the human body. Illness or chemical poisoning of the body may inhibit the activity of bone marrow, and impair the production of blood cells. In this case, the blood begins to circulate more and more abnormal cells and the number of healthy begins to steadily decrease. This can cause the development of certain diseases imperceptibly blood and hematopoietic system, which can even lead to death. Also, cancer treatments such as chemo and radiation therapy can cause impaired bone marrow function. The only salvation for the patient’s bone marrow transplant is either (as in the case of acute leukemia) or the use of new innovative drugs spot. Research on many innovative drugs have demonstrated efficacy in patients in response. Drugs such as: azacitidina (Vidaza), decitabine (Decogen) and lenalidomide (Revlimid). Azacitidina (Vidaza) and decitabine (Decogen) are in the final phase of clinical trials and have already pre-registered in the United States of America.

To jest tylko fragment artykułu. Aby przeczytać całość, przejdź do Czytelni medycznej.